The Influence of Metformin on Chronic Heart Failure Clinical Course in Patients With Prediabetes
Status:
Completed
Trial end date:
2019-11-15
Target enrollment:
Participant gender:
Summary
It is well known fact, that prediabetes is a predictor of high cardiovascular mortality,
increasing the risk of developing such adverse cardiovascular events as myocardial
infarction, stroke and sudden cardiac death. The key pathogenetic link in development of
carbohydrates metabolism disorders (CMD) is insulin resistance (IR), which is one of the
crucial mechanisms for the development and progression of chronic heart failure (CHF). IR
disrupts the functioning of the myocardium due to endothelial dysfunction, inflammation,
oxidative stress, remodeling and impaired myocardial metabolism. In condition of a
combination of CMD and CHF the reverse development of hyperglycemia is also difficult due to
hyperactivation of neurohormonal systems - renin-angiotensin-aldosterone system, in
particular.
So, drug therapy should neutralize the undesirable metabolic effects of hyperglycemia on the
course of CHF, as well as prevent the development of micro- and macrovascular complications.
The study will investigate the ability of metformin to impact on clinical and laboratory
(neurohormonal, lipid profiles, renal function) parameters of ischemic etiology heart failure
patients with prediabetes, as well as their quality of life and prognosis (incidence of
adverse cardiovascular events). These tests will be assessed at the beginning and repeated
after one year. At the end of the study we will investigate the difference between lifestyle
modification effect and metformin treatment.
The study is funded by Ministry of Education and Science of Kyrgyz Republic.
Phase:
Phase 4
Details
Lead Sponsor:
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov